Abstract: The invention relates to the extraction of organic compounds from mixtures of said compounds with water, using a nanoporous carbon membrane. The invention can be used in any field where it is desired to separate an organic compound of interest from water, such as the drying of alcohols or alkanes.
Type:
Grant
Filed:
March 27, 2017
Date of Patent:
January 3, 2023
Assignees:
Paris Sciences et Lettres, Université Paris Cité, Centre National De La Recherche Scientifique (CNRS), Sorbonne Universite
Abstract: The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
November 29, 2022
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Cité
Abstract: The present invention relates to a method for detecting or quantifying deoxyribonucleic acid (DNA) of human immunodeficiency virus 2 (HIV-2) in a sample containing DNA comprising: a) performing a real-time polymerase chain reaction (PCR) on the sample, or a fraction thereof comprising DNA, with at least two sets of primers and probe each respectively comprising two primers and a labeled probe for the detection or quantification of HIV-2 DNA, at least one of the sets is selected from the group consisting of: a set comprising a primer comprising or consisting of a sequence SEQ ID NO: 1 or a sequence having al least 90% identity to SEQ ID NO: 1, a primer comprising or consisting of a sequence SEQ ID NO: 2 or a sequence having 90% identity to SEQ ID NO: 2 or the complement of these sequences, and a labeled probe comprising or consisting of a sequence SEQ ID NO: 3, or a sequence having at least 90% identify to SEQ ID NO: 3 or the complement of these sequences, and a set comprising a primer comprising or consisting
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
October 4, 2022
Assignees:
UNIVERSITÉ PARIS CITÉ, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CHU DE ROUEN, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN, UNIVERSITÉ PARIS NORD
Abstract: The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.
Type:
Grant
Filed:
May 24, 2017
Date of Patent:
October 4, 2022
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS-SACLAY, UNIVERSITE PARIS CITE
Inventors:
Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli
Abstract: Disclosed are organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. Also disclosed are pharmaceutical compositions including such OCTs inhibitor of Formula (A) and their use for treating and/or preventing mood-related disorders such as depressive disorders.
Type:
Grant
Filed:
July 13, 2018
Date of Patent:
August 16, 2022
Assignees:
SORBONNE UNIVERSITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS CITÉ
Inventors:
Sophie Gautron, Nicolas Pietrancosta, Francine Acher, Laetitia Chausset-Boissarie
Abstract: The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
July 19, 2022
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ PARIS CITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
Abstract: The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
July 12, 2022
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS CITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS XIII PARIS-NORD, ÉCOLE SUPÉRIEUR DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE PARIS, SORBONNE UNIVERSITE
Inventors:
Ludwik Leibler, Anne Meddahi-Pellé, Didier Letourneur, Alba Marcellan-Parisot
Abstract: The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
Type:
Grant
Filed:
October 24, 2019
Date of Patent:
June 14, 2022
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS CITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, IMAGINE
Inventors:
Laurence Legeai-Mallet, Arnold Munnich, Patricia Busca, Florent Barbault